LSU Health New Orleans Opens Clinical Trial Studying Liquid Aspirin for Early COVID-19
February 11, 2022
Frank Lau, MD, Associate Professor of Surgery at LSU Health New Orleans School of Medicine, is the principal investigator. Supported by UK-based Innovate Anti-infectives Ltd., it uses Enhanced Liquid Aspirin (ELA), a drug formulated by Innovate Anti-infectives Ltd., led by Medical Director Jimmy Stuart & CEO Simon Cohen.
Although COVID-19 is classified as an acute respiratory infection, COVID-associated coagulopathy (CAC) has been linked to death and severe illness. This condition can cause abnormalities of blood flow, including the tendency toward prolonged or excessive clotting. Anticoagulant therapies such as heparin have been shown to reduce CAC-related mortality and are now standard of care for hospitalized COVID-19 patients. However, no data regarding outpatient management of COVID-19 with anticoagulant therapies have been published.The trial is a randomized, double-blind placebo control study. Participants will be randomly assigned to one of two study arms. Participants in Arm 1 will receive a placebo, which is an inactive substance of soybean oil. Participants assigned to Arm 2 will receive 150 mg of liquid aspirin daily.
As with any study, there are risks, including allergic reactions to study drugs. Although conventional aspirin is an over-the-counter medication that is routinely taken by patients who are at risk for cardiovascular events, some side effects have been noted. Possible side effects include nausea, upset stomach, heartburn, gastritis, gastric bleeding, soft tissue bleeding or bruising. Participants could also experience intolerance and allergic reaction to the soybean oil in the placebo. Patients with preexisting risk factors of bleeding will be excluded from the study.If the study’s hypothesis is correct, subjects who receive the treatments may benefit through reduced disease severity and reduced chances of hospitalization, although no direct medical benefit can be guaranteed. Study results may lead to a low-risk and early outpatient treatment method to reduce the hospitalization rate for newly diagnosed COVID-19 patients. This study will also help the researchers learn more about how liquid aspirin and serum vitamin D levels can affect COVID-19 disease severity and hospitalizations. This information may help in the treatment of future patients with COVID-19.
“COVID-19 has affected millions of people world-wide,” said Dr. Jimmy Stuart of Innovate Anti-Infectives Ltd. “The available vaccines have proven to be effective against COVID-19 but with some limitations. In particular, the protection they give seems to decline after six months. While vaccines will continue to be the main defense against COVID, we also need to develop medications that are effective in treating this disease.”For more information, contact Catherine Powell at 504-568-2202.
______________________________________________________________________________________________________________ LSU Health Sciences Center New Orleans (LSU Health New Orleans) educates Louisiana's health care professionals. The state's health sciences university leader, LSU Health New Orleans includes a School of Medicine with branch campuses in Baton Rouge and Lafayette, the state's only School of Dentistry, Louisiana's only public School of Public Health, and Schools of Allied Health Professions, Nursing, and Graduate Studies. LSU Health New Orleans faculty take care of patients in public and private hospitals and clinics throughout the region. In the vanguard of biosciences research, the LSU Health New Orleans research enterprise generates jobs and enormous annual economic impact. LSU Health New Orleans faculty have made lifesaving discoveries and continue to work to prevent, advance treatment or cure disease. To learn more, visit http://www.lsuhsc.edu, http://www.twitter.com/LSUHealthNO, or http://www.facebook.com/LSUHSC.
Follow Us 
Leslie Capo
Office: 504-568-4806
Cell: 504-452-9166
lcapo@lsuhsc.edu